MX2012001722A - Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. - Google Patents

Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.

Info

Publication number
MX2012001722A
MX2012001722A MX2012001722A MX2012001722A MX2012001722A MX 2012001722 A MX2012001722 A MX 2012001722A MX 2012001722 A MX2012001722 A MX 2012001722A MX 2012001722 A MX2012001722 A MX 2012001722A MX 2012001722 A MX2012001722 A MX 2012001722A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable acid
new method
added salts
ivabradine
Prior art date
Application number
MX2012001722A
Other languages
English (en)
Other versions
MX337997B (es
Inventor
Jean-Louis Peglion
Aimee Dessinges
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43901397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012001722(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2012001722A publication Critical patent/MX2012001722A/es
Publication of MX337997B publication Critical patent/MX337997B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/16—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton

Abstract

Procedimiento de síntesis de la ivabradina de fórmula (I): (ver fórmula (I)) y de sus sales de adición a un ácido farmacéuticamente aceptable.
MX2012001722A 2011-02-14 2012-02-09 Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. MX337997B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1100446A FR2971507B1 (fr) 2011-02-14 2011-02-14 Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable

Publications (2)

Publication Number Publication Date
MX2012001722A true MX2012001722A (es) 2012-08-29
MX337997B MX337997B (es) 2016-03-30

Family

ID=43901397

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001722A MX337997B (es) 2011-02-14 2012-02-09 Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.

Country Status (35)

Country Link
US (1) US8476426B2 (es)
EP (1) EP2487158B1 (es)
JP (1) JP5475813B2 (es)
KR (1) KR101372389B1 (es)
CN (1) CN102633720B (es)
AR (1) AR085344A1 (es)
AU (1) AU2012200439B2 (es)
BR (1) BR102012003254A2 (es)
CA (1) CA2767893C (es)
CL (1) CL2012000270A1 (es)
CY (1) CY1113983T1 (es)
DK (1) DK2487158T3 (es)
EA (1) EA020735B1 (es)
ES (1) ES2408213T3 (es)
FR (1) FR2971507B1 (es)
GE (1) GEP20135970B (es)
HR (1) HRP20130368T1 (es)
IN (1) IN2012DE00289A (es)
JO (1) JO2930B1 (es)
MA (1) MA34990B1 (es)
ME (1) ME01479B (es)
MX (1) MX337997B (es)
MY (1) MY171954A (es)
NZ (1) NZ598138A (es)
PE (1) PE20121741A1 (es)
PL (1) PL2487158T3 (es)
PT (1) PT2487158E (es)
RS (1) RS52699B (es)
SA (1) SA112330272B1 (es)
SG (1) SG183607A1 (es)
SI (1) SI2487158T1 (es)
TW (1) TWI430993B (es)
UA (1) UA110326C2 (es)
UY (1) UY33893A (es)
WO (1) WO2012110716A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827019B (zh) * 2012-09-12 2014-12-10 江苏宇田生物医药科技有限公司 一组新的苯并环丁烷化合物及其在化学合成中的应用
CN103848789B (zh) * 2012-11-29 2016-05-18 江苏恒瑞医药股份有限公司 一种伊伐布雷定的制备方法
CN104447553B (zh) * 2013-09-22 2017-02-01 广东众生药业股份有限公司 伊伐布雷定及其中间体的制备方法
CN104829470B (zh) * 2015-04-20 2017-08-25 江苏宇田医药有限公司 一组合成伊伐布雷定的中间体化合物及其应用
KR200488336Y1 (ko) 2017-01-04 2019-01-15 한전케이피에스 주식회사 저압터빈의 구동기 커플링용 분해 조립 작업대

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US179316A (en) * 1876-06-27 Improvement in processes of preparing and producing colored photographs on glass
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868775B1 (fr) * 2004-04-13 2008-04-11 Servier Lab Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
EP2460797A3 (en) * 2006-11-30 2012-12-05 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
WO2008146308A2 (en) * 2007-05-30 2008-12-04 Ind-Swift Laboratories Limited Process for the preparation of ivabradine hydrochloride and polymorph thereof
FR2933975B1 (fr) * 2008-07-17 2011-02-18 Servier Lab Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
CN101723897B (zh) * 2008-10-31 2011-11-16 齐鲁制药有限公司 伊伐布雷定的合成方法
ES2402765T3 (es) * 2008-12-22 2013-05-08 Krka, D.D., Novo Mesto Procedimiento de preparación de ivabradina
FR2940287B1 (fr) * 2008-12-24 2010-12-24 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
FR2941695B1 (fr) * 2009-02-04 2011-02-18 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2943668B1 (fr) * 2009-03-31 2011-05-06 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.

Also Published As

Publication number Publication date
TW201307293A (zh) 2013-02-16
KR20120093105A (ko) 2012-08-22
UY33893A (es) 2012-08-31
JO2930B1 (en) 2015-09-15
CN102633720B (zh) 2014-04-16
PL2487158T3 (pl) 2013-06-28
GEP20135970B (en) 2013-11-11
DK2487158T3 (da) 2013-05-21
US8476426B2 (en) 2013-07-02
JP5475813B2 (ja) 2014-04-16
SA112330272B1 (ar) 2014-06-25
AU2012200439B2 (en) 2015-02-19
AU2012200439A1 (en) 2012-08-30
MA34990B1 (fr) 2014-04-03
NZ598138A (en) 2012-11-30
TWI430993B (zh) 2014-03-21
EP2487158B1 (fr) 2013-02-20
IN2012DE00289A (es) 2015-04-10
BR102012003254A2 (pt) 2013-07-23
EP2487158A1 (fr) 2012-08-15
CL2012000270A1 (es) 2014-08-18
EA020735B1 (ru) 2015-01-30
CA2767893A1 (fr) 2012-08-14
AR085344A1 (es) 2013-09-25
KR101372389B1 (ko) 2014-03-11
CY1113983T1 (el) 2016-07-27
PE20121741A1 (es) 2012-12-22
EA201200123A1 (ru) 2012-11-30
ME01479B (me) 2014-04-20
MY171954A (en) 2019-11-08
UA110326C2 (uk) 2015-12-25
RS52699B (en) 2013-08-30
FR2971507A1 (fr) 2012-08-17
CN102633720A (zh) 2012-08-15
ES2408213T3 (es) 2013-06-19
SG183607A1 (en) 2012-09-27
CA2767893C (fr) 2014-02-04
JP2012167091A (ja) 2012-09-06
FR2971507B1 (fr) 2013-01-18
PT2487158E (pt) 2013-03-07
MX337997B (es) 2016-03-30
US20120208996A1 (en) 2012-08-16
SI2487158T1 (sl) 2013-06-28
WO2012110716A1 (fr) 2012-08-23
HRP20130368T1 (en) 2013-05-31

Similar Documents

Publication Publication Date Title
JO2807B1 (en) A new process for the synthesis of ivabradine and its addition salts with pharmaceutically acceptable acid.
GEP20135960B (en) New method of synthesis of ivabradine and pharmaceutically acceptable acid-additive salts thereof
MY150014A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
MY169295A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
MX2012001722A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
MY145611A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
JO2854B1 (en) A new method for the synthesis of anfabradine and its added salts with acid is pharmaceutically acceptable.
UA111329C2 (uk) Спосіб синтезу івабрадину і його адитивних солей з фармацевтично прийнятною кислотою
JO3276B1 (ar) طريقة لتخليق 3، 4-داي ميثوكسي باي سيكلو [4. 2. 0] أوكتا-5،3،1-تراي إين-7-كربونيتريل واستخدامها لتخليق ايفابرادين والأملاح المضافة منه مع حمض مقبول صيدلانيا.
MX2013002990A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
JO3189B1 (ar) طريقة جديدة لتخليق (e2) -3- (3, 4- داي ميثوكسي فينيل)بروب-2 - يننيتريل واستخدامها لتخليق ايفابرادين والاملاح المضافة منها مع حمض مقبول صيدلانيا
MD4477B1 (ro) Procedeu de sinteză a 3-(2-bromo-4,5-dimetoxifenil)propannitrilului şi aplicarea acestuia în sinteza ivabradinei şi a sărurilor sale de adiţie cu un acid farmaceutic acceptabil
MY160928A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
SG165255A1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid

Legal Events

Date Code Title Description
FG Grant or registration